Definitive Contract 75A50123C00060
Award Date
9/22/23
Potential Completion Date
9/30/34
Potential Value
$311M
Awardee
Eitr Biologics, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $750,000.00 firm fixed price delivery order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc. for the development of novel nanotherapeutic approaches for the treatment of pneumonic plague. The order is part of a larger $4.39 million Indefinite Delivery Vehicle (IDV) contract between Eitr Biologics and DHA to advance the research and development of nanotherapeutics to combat biological threats. The work will be performed in San Diego, California and involves...
This federal contract award to Eitr Biologics, Inc. for $499,896.06 was issued by the Defense Health Agency (DHA) on July 1, 2024. The award is for the development of a novel therapeutic medical countermeasure capable of protecting against pneumonic unencapsulated Yersinia pestis, the causative agent of pneumonic plague. The contract is a Firm Fixed Price Delivery Order with a completion date of June 30, 2025. This award is part of a larger Indefinite Delivery Vehicle (IDV) held by Eitr...
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an...
This is a $1,403,362,669.10 cost-plus-fixed-fee contract awarded by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company manufacturing medical countermeasures and pharmaceuticals. The contract, which has a period of performance through September 29, 2026, is for the development of filovirus treatments. Emergent has received over $1.3...
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to Elusys Therapeutics Inc. The contract, valued at $13,853,653.00, is for biomedical research and development services, ranging from basic to advanced capabilities. The contract is a Definitive Contract with a Cost No Fee pricing type, and does not have a set-aside designation. The period of performance runs from September...
This $135,212,671.14 federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to Gigagen Inc., a for-profit foreign-owned company, for the development of a next-generation recombinant polyclonal antibody discovery platform to produce medical countermeasures.
The contract was awarded under BARDA's (Biomedical Advanced Research and Development Authority) Broad Agency...
This is a $204,984,698.95 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Biocryst Pharmaceuticals Inc. for the advance development of a new antiviral agent for influenza under the Pandemic Influenza Preparedness program. The contract does not have a set-aside designation, indicating Biocryst competed for the award in the open market. Biocryst is a biotechnology...
This is a $11,097,619.00 definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Regeneron Pharmaceuticals Inc. The contract has a period of performance through September 30, 2022 and is a cost-plus-fixed-fee arrangement.
The contract is not associated with a set-aside and appears to be part of the government's response to the COVID-19 pandemic, potentially related to Operation Warp Speed. Regeneron is a pharmaceutical...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc. The $29,026,970.00 cost-plus-fixed-fee contract was awarded on September 9, 2019 to perform work under HHS-NIH-NIAID-BAA2018. The contract has an ultimate completion date of August 17, 2024 and does not have a set-aside...
This firm fixed-price contract, valued at $762,812,695, was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Emergent Product Development Gaithersburg Inc., a for-profit limited liability company. The contract is for the development of medical countermeasures (MCM) that can be deployed in the event of a filovirus outbreak, which is a crucial component of the U.S. government's outbreak...